Abstract P045: The Association Between Cigarette Smoking and Cardiovascular Inflammation: The Genetic Epidemiology Network of Arteriopathy Study
Background: To assist in the regulation of novel and existing tobacco products, there is a need to identify biomarkers of early cardiovascular damage following tobacco exposure. Our prior work suggests that inflammatory markers, in particular high-sensitivity C-reactive protein (hsCRP), may be sensitive markers of tobacco mediated cardiovascular damage. We aimed to further study the association of smoking and inflammation in a cohort with hsCRP and 11 other measures of inflammation associated with cardiovascular disease (CVD) risk.
Methods: We conducted a cross-sectional analysis on 2,550 siblings diagnosed with essential hypertension prior to age 60 years. Cigarette smoking was assessed by status, intensity, pack-years, and time since quitting. We modeled each biomarker per standard deviation after natural log transformation and evaluated the association between smoking and biomarkers using generalized estimating equations (GEE) to account for intra-familial correlations. Models were adjusted for demographics and CVD risk factors.
Results: The mean age of participants was 61±10 years; 64.5% were women and 54.4% African American. There were 12.2% current smokers and 32.2% former smokers. Compared to never smokers, current smokers had significantly higher levels of 8 inflammatory biomarkers (Table). In analyses of other smoking variables, there was a consistent association with hsCRP but not other biomarkers. HsCRP was positively associated with pack-years of cigarette smoked and inversely associated with time since quitting, but not with smoking intensity. There was a significant difference in hsCRP levels among current smokers by race (p for interaction=0.005). On average, hsCRP was higher among African American [0.445 (0.283, 0.606)] compared to White smokers [0.183 (0.011, 0.356)].
Conclusion: Biomarkers of inflammation, especially hsCRP, may allow for early detection of cardiovascular injury due to cigarette smoking and could be useful for the study and regulation of emerging tobacco products.
Author Disclosures: M. Tibuakuu: None. D. Kamimura: None. S. Kianoush: None. A. DeFilippis: None. M. Al Rifai: None. K.R. Butler: None. T.H. Mosley: None. M.E. Hall: None. M.J. Blaha: None.
- © 2017 by American Heart Association, Inc.